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1  | INTRODUC TION
Oral cancer is one of the leading cancers with a nearly 50% mortal-
ity rate, and the overall 5-year survival rate is approximately 60%. 
Tobacco, alcohol, and HPV infection are the most important risk fac-
tors for oral squamous cell carcinoma (OSCC).1 Conventional ther-
apy for OSCC includes multimodal approaches consisting of surgery, 
radiation, chemotherapy, and combinations based on the stage at 
the time of diagnosis.2,3 Recent advances in cell and molecular biol-
ogy have made personalized medicine viable.
Epigenetic modifications and post-translational protein alterations 
have become novel targets for anticancer therapies. The acetylation of 
the ɛ-amino group present at lysine residues of histone proteins plays a 
central role in gene transcription and cell survival. Histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs) control the acetyla-
tion levels of histones and chromatin accessibility.4,5
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Abstract
Introduction: Alterations of the epigenome may influence cancer initiation and pro-
gression. At the cellular level, histones are key regulators of chromatin accessibility 
and gene transcription; thus, the inhibition of histone deacetylase enzymes (HDACs) 
constitutes an attractive target for therapy. In this study, we investigated the effects 
of the HDAC inhibitor entinostat on oral squamous cell carcinoma (OSCC).
Materials and Methods: We tested the effects of entinostat on OSCC cell lines. Cell 
viability and growth were analyzed using MTT assay. Cell cycle analysis, cell apopto-
sis, cancer stem cell (CSC) content, and the concentration of reactive oxygen species 
(ROS) in OSCC tumor cells were assessed using flow cytometry. The expression of 
histones and cell cycle regulatory proteins was examined by Western blot.
Results: The administration of entinostat resulted in reduced proliferation of OSCC 
cells, followed by cell cycle arrest at the G0/G1 phase, as well as substantial tumor ap-
optosis. We found an increase in ROS production and significant reductions in CSCs. 
We also found that entinostat caused increased acetylation histone H3 and histone 
H4, and changes in the expression of cell cycle-associated proteins such as p21.
Conclusion: This study indicates that entinostat is a potential novel therapeutic agent 
for OSCC by halting tumor proliferation, inducing cytotoxicity and intracellular ROS, 
and attacking the CSCs.
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Entinostat (SNDX-275 and MS-275) is the first amino-ben-
zamide–based HDAC inhibitors (HDACi) currently being tested in 
several clinical trials.6-8 Entinostat is a bioavailable class I HDACi 
with a long half-life. In vitro and in vivo studies have shown that 
the administration of entinostat as a single or combined therapy 
represents a promising drug for managing breast and esophageal 
cancers due to its antiproliferative and pro-apoptotic effects.9,10 
Nevertheless, there is a gap in the current knowledge of the poten-
tial efficacy of entinostat in managing OSCC. Here, we investigate 
the biological effects of entinostat on the behavior of OSCC.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and culture conditions
Oral squamous cell carcinoma cell lines WSU-HN6 and WSU-HN12 
(primary OSCC and metastatic OSCC from the tongue, respectively) 
and an immortalized keratinocyte (HaCat) cell line were kept in a 5% 
CO2-humidified incubator at 37°C and cultured in Dulbecco's modi-
fied Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1% antibiotic.
2.2 | Cell proliferation, viability, and IC50
Cell viability was assessed by the MTT assay (MTT Cell Proliferation 
Assay Kit, Trevigen) following the manufacturer's protocol. The ex-
periments were done in sextuplicate. Dose-response curves (IC50) 
for entinostat were performed using a drug concentration range of 
0.0001-1000 µM for 24 hours. Control cells received vehicle alone.
2.3 | Cell cycle assay
Cells were seeded and treated with entinostat and vehicle for 
24 hours. Cells were fixed with 100% cold ethanol, following the 
addition of propidium iodide solution (PI-RNase) and incubation at 
room temperature in the dark for 20 minutes. Samples were ana-
lyzed by flow cytometry using Accuri C6 Plus Flow Cytometer (BD 
Biosciences) and Accuri CFlow Plus software. The assays were run 
in triplicates.
2.4 | Cell apoptosis assay
Cell apoptosis was assessed using CellEvent Caspase-3/7 Green 
Flow Cytometry Assay (Life Technologies) according to the manu-
facturer's instructions. Briefly, 1 µL of CellEvent Caspase-3/7 Green 
Detection Reagent was added to samples containing 1 mL of cell 
suspension at 1 × 106 cells/mL and incubated for 25 minutes at 37°C. 
Then, 1 µL of 1 mM SYTOX AADvanced dead cell stain solution was 
added to samples and incubated for 5 minutes at 37°C. A minimal of 
triplicates assays were performed. The flow cytometry was used to 
analyze the samples.
2.5 | ROS detection assay
Cells were trypsinized and centrifuged at 400 g for 5 minutes. Next, 
cells were resuspended in fresh medium at the concentration of 
1 × 105 cells/mL. Cells were incubated with ROS/superoxide solu-
tion (Enzo Life Sciences) along with the administration of entinostat 
or vehicle as control for 1 hour at 37°C in the dark. Unstained cells 
were used to determine the negative population. Quality controls 
were performed using the ROS inducer pyocyanin as positive con-
trol and ROS inhibitor N-acetyl-L-cysteine as negative control. ROS 
levels were identified by flow cytometry.
2.6 | Cancer stem cell assay
Tumor cells receiving entinostat or vehicle control were trypsinized, 
counted, and resuspended in ALDEFLOUR assay buffer (1 × 106 cells/
mL) containing ALDH substrate (ALDEFLOUR Kit—STEMCELL 
Technologies). The assay was carried out following the manufactur-
er's protocol. Cells were stained with anti-CD44 antibody conjugated 
with APC (Clone G44-26; BD Biosciences). Negative controls received 
the ALDH inhibitor diethylaminobenzaldehyde (DEAB). Additional 
control samples stained for CD44 and unstained cells were also used 
in the assay. All experiments were performed in sextuplicate. All sam-
ples were analyzed using flow cytometry.
2.7 | Western blot analysis
Entinostat and vehicle-treated cells were washed with cold PBS, 
lysed, and proteins were denatured (boiled) following run on SDS-
PAGE. Western blotting was performed using standard techniques. 
Primary anti-human antibodies (Table S1) were diluted in 5% bo-
vine serum albumin (BSA) or 5% milk/TBS-T) and added to the WB 
membrane (4°C/overnight). The secondary antibodies (horseradish 
peroxidase-HRP substrate) were diluted in 5% milk/TBS-T (1:3000 
dilution). The signal was captured using the enhanced chemilumines-
cence (ECL) system. GAPDH protein was used as a loading control.
2.8 | Statistical analysis
Statistical analyses for cell viability assays and flow cytometry experi-
ments were carried out by Student's t test, Kruskal-Wallis, and Welch's 
t test using GraphPad software by PRISM (GraphPad Software). Dose-
response curves were created using GraphPad version 7.0. All flow cy-
tometry experiments were repeated in sextuplicate. The P values ≦ .05 
reflect statistical significance. Asterisks indicate statistical significance 
(*P ≦ .05; **P ≦ .01; ***P ≦ .001; ****P ≦ .0001).
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3  | RESULTS
3.1 | Entinostat reduces OSCC cell viability and 
SIRT1 levels
The mammalian genome is packed into the chromatin, which 
consists of DNA together with histone and non-histone proteins. 
The epigenome constitutes a group of molecules and chemical 
compounds capable of modifying gene transcription. Changes 
to the epigenome can contribute to the dysregulation of key 
cellular processes, including cellular proliferation.11 Here, we 
investigated whether entinostat-induced inhibition of HDAC 
1 and HDAC 3 would affect the proliferation of OSCC tumor 
cells. We found that the administration of entinostat resulted in 
a dose-dependent reduction in the proliferation of cancer cells 
(Figure 1A-C). Next, we performed the cell viability assay and de-
termined the IC50 values for all cell lines, which were 18.74 µM 
for keratinocyte, 0.54 µM for WSU-HN6, and 23.31 µM for 
WSU-HN12 (Figure 1D-F). We also analyzed the ability of en-
tinostat in modifying the epigenome of tumor cells through the 
identification of the acetylation levels of histones H3 and H4. We 
observed increased acetylation of histones H3 and H4 in control, 
WSU-HN6, and WSU-HN12 cells, compared with the vehicle-
treated cells. Notably, there was a decrease in the enzyme dea-
cetylase SIRT1 in all cells, confirming the efficacy of entinostat as 
a potent inhibitor of HDAC (Figure 1G).
F I G U R E  1   Effect of entinostat on oral 
cancer growth and expression of histones 
H3 and H4. A-F, Graphic representation 
of entinostat concentrations used in 
the MTT assay to determine the 50% 
inhibitory concentration of cell viability 
(IC50) of each cell line in 24 h of treatment 
and their respective dose-response curves 
(percentage mean ± SEM). Note that 
entinostat decreased the cell proliferation 
of OSCC lines and keratinocytes. IC50 for 
keratinocyte is 18.74 µM, WSU-HN6 is 
0.54 µM, and WSU-HN12 is 23.31 µM. 
G, Entinostat increased the expression 
of acetylated histones H3 and H4 and 
reduced the protein levels of SIRT1
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F I G U R E  2   Effect of entinostat on cell cycle and expression of regulatory proteins. A-I, Representation of the cell distribution in the G0/
G1, synthesis (S), and G2/M phases of the cell cycle after 24 h of treatment with entinostat using the IC50 values previously defined for each 
cell line. There were statistically significant increases in G0/G1 and S phases in keratinocytes (**** = P ≦ .0001), WSU-HN6 (* = P ≦ .05), and 
WSU-HN12 (**** = P ≦ .01) (NS ≥ 0.05. Not significant; percentage mean ± SEM). J, Entinostat reduced p53 expression in keratinocyte. The 
absence of p53 was observed in WSU-HN12. Entinostat-induced expression of p21 in all cell lines
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3.2 | Entinostat activates p21 and induces cell 
cycle arrest
Next, we investigated the impact of entinostat on the tumor cell 
cycle using flow cytometry. Overall, we found that entinostat stimu-
lates cells to undergo G0/G1 cell cycle arrest in all analyzed cell lines 
(Figure 2A-F). While OSCC tumor cells did not present an increase 
in the number of cells undergoing DNA synthesis (S phase) upon 
administration of entinostat (ns—P > .05), we observed that normal 
epithelial cells progressed from G0/G1 to S phase during entinostat 
treatment compared with the vehicle-treated group (P ≦ .001) (Fig. 
G-I). Our data support the fact that the administration of entinostat 
is efficient in enhancing the number of cells to undergo G0/G1 cell 
cycle arrest, while only normal keratinocyte cells responded to the 
treatment by increasing DNA synthesis (Figure 2G).
Non-histone targets of HDAC may include transcription factors 
and other proteins involved in cancer development and progres-
sion.12 Interestingly, we observed a reduced expression of the p53 
protein in keratinocyte cells after entinostat treatment; the absence 
of this protein was found in the WSU-HN12 cells treated with ve-
hicle or entinostat (Figure 2J). p53 is considered to be one of the 
first non-histone targets for acetylation and deacetylation. In fact, 
HDACs can deacetylate p53 affecting its transcriptional activity.13 
Furthermore, we observed that p21 was upregulated in all cells re-
ceiving entinostat (Figure 2J).
3.3 | Entinostat triggers the production of ROS and 
induces cellular apoptosis
Previous studies have reported that keratinocytes have a lower re-
active oxygen species (ROS) levels compared with cancer cells.14 
Here, we hypothesize that cancer cells are more vulnerable to HDAC 
inhibitors due to its sensitivity to the accumulation of ROS intracellu-
lar levels. Indeed, we found that ROS levels are higher in OSCC cells 
treated with entinostat. Nonetheless, all cell lines responded to the 
administration of entinostat by significantly accumulating ROS (ke-
ratinocytes and WSU-HN6—P ≦ .05; WSU-HN12—P ≦ .01). Similar to 
ROS, we also observed the accumulation of superoxide (SO) (P ≦ .05) 
(Figure 3A-C). Following, we explored the levels of cells undergo-
ing apoptosis in the treated group compared with vehicle controls. 
We observed that entinostat significantly induced programmed cell 
death in all cell lines (Figure 4A-F).
3.4 | Administration of entinostat decreases the 
population of CSC and BMI1 levels
CSCs correspond to a subpopulation of cancer cells presenting self-
renewal properties and enhanced engraftment abilities capable of 
generating new tumors.15 These cells are also involved in the de-
velopment of tumor resistance to chemotherapy and further tumor 
recurrences. Here, we investigated whether the administration of 
entinostat would impact the population of CSC from OSCC, and with 
that, paving the way for epigenetic modifications as novel therapeu-
tic strategies to manage head and neck cancers. We evaluated the 
effect of entinostat on CSCs using well-characterized OSCC stem 
cell markers CD44 and ALDH.16 We observed a reduction in more 
than 50% of CSC after the administration of entinostat for 24 hours 
(Figure 5A-D). These results suggest that the HDAC inhibitor enti-
nostat is effective in reducing the population of CSC from OSCC tu-
mors. We also analyzed the expression of BMI1, a polycomb group 
repressor, involved in governing the self-renewal capacity of CSCs.17 
Our experiments demonstrated that the administration of entinostat 
reduced BMI1 expression (Figure 5E). We observed no change in the 
protein levels of PTEN (phosphatase and tensin homolog deleted 
F I G U R E  3   Effect of entinostat on the 
production of reactive oxygen species 
(ROS) and superoxide (SO). A-C, After 
24-hour treatment with entinostat, using 
the IC50 values defined for each cell line, 
there was an increase in the generation of 
both ROS and superoxide in all cell lines 
(fold increase mean ± SEM; * = P ≦ .05. 
** = P ≦ .01)
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on chromosome 10) upon administration of entinostat (Figure 5E). 
PTEN is a tumor suppressor gene frequently found mutated or 
downregulated in cancer. Meng and collaborators showed that PTEN 
activation by blocking HDAC6 contributed to cancer inhibition.18 
Therefore, non-selective HDAC inhibitors do not interfere with the 
endogenous levels of the tumor suppressor PTEN that corroborated 
to the potential use of entinostat as a therapy for OSCC.
In summary, the administration of entinostat to OSCC leads to 
cell cycle arrest, apoptosis, and accumulation of ROS and superox-
ide, along with the depletion of CSCs (Figure 6).
4  | DISCUSSION
Changes to the epigenome can contribute to cancer formation 
and progression. Epigenetic modifications are associated with 
the deregulation of important biological processes, such as cell 
cycle progression and DNA repair, which can be controlled by 
environmental stressors. Enzymes that participate in epigenetic 
events are often found dysregulated in human cancers. More spe-
cifically, alterations of two families of chromatin enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), are 
reported in many tumors.19 The identification and targeting of epi-
genetic-associated dysfunctional enzymes have spawned the de-
velopment of new inhibitors capable of targeting the epigenome.5 
Fine-tuning the balance between HDACs and HATs is proved to be 
an effective antitumor therapy, which led to the development of 
HDAC inhibitors.5 HDACi interfere with the cancer cell cycle, trig-
gering cellular differentiation and death, decrease angiogenesis, 
and modify the immune response. HDACi are currently approved 
for the treatment of T-cell lymphoma (eg, belinostat, romidepsin, 
and vorinostat), and multiple myeloma (panobinostat), while ad-
ditional HDACi are under clinical investigation for hematopoietic 
cancers.
F I G U R E  4   Effect of entinostat on cell 
death in all cell lines. A-F, Flow cytometry 
was used to analyze cell death events. 
Results are shown in dot-plot diagrams. 
The apoptotic cells are shown in red. 
The bar graph displays the results of the 
apoptosis analyses. Each cell line was 
treated with entinostat or vehicle for 24 h. 
Note that entinostat resulted in apoptotic 
cells, especially in the WSU-HN12 cells 
(percentage mean ± SEM; ** = P ≦ .01, 
**** = P ≦ .1)
     |  777MARQUES Et Al.
F I G U R E  5   Flow cytometric analysis 
of OSCC cells treated with entinostat for 
the expression of ALDH and CD44, and 
effect of entinostat on BMI1 expression. 
A-D, After 24-hour treatment using 
the IC50 values previously defined for 
each cell line, there was a statistically 
significant reduction in stem cells 
(percentage mean ± SEM; * = P ≦ .05; 
** = P ≦ .01). Cells exposed to entinostat 
for 24 h were collected and assessed for 
ALDH activity and CD44 positivity using 
fluorescence-activated cell sorting (FACS). 
Dot plots display the cancer stem cells 
(CSC or CD44+ and ALDHbright cells are 
displayed as green dots, and tumor cells 
(TCs) are displayed as black dots). The 
results for the analyses of cancer stem 
cells are represented in the bar graphs. E, 
Entinostat led to the reduction in BMI1 
protein levels after treatment. Entinostat 
does not affect PTEN protein levels
F I G U R E  6   Schematic representation 
shows the main effects of entinostat 
treatment on oral squamous cell 
carcinoma. Entinostat treatment of oral 
squamous cell carcinoma (OSCC) cells 
resulted in cell cycle arrest, tumor cell 
apoptosis, accumulation of ROS and 
superoxide, and depletion of cancer stem 
cells (CSCs)
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Entinostat is a synthetic small-molecule benzamide derivative 
that inhibits HDAC activity. The efficiency of entinostat was demon-
strated in animal models leading to the hyperacetylation of histones 
and consequent increased gene expression. The present study has 
demonstrated that even at low concentrations, entinostat is able 
to reduce the cellular viability of OSCC cells in a dose-dependent 
fashion. These effects were observed in the WSU-HN6 cell line. 
Nevertheless, the WSU-HN12 cell line required a higher inhibitory 
drug concentration, similar to the inhibitory concentration affect-
ing the normal keratinocytes. Although entinostat was effective on 
OSCC cells, it was not selective to cancer cells. Other studies have 
also shown that histone deacetylase inhibitors, such as vorinostat 
and resminostat, cause cytotoxicity in normal keratinocytes.20,21
Mutations and inactivation of the p53 have been reported in 
more than 50% of all carcinomas.22 It is well known cancer cell re-
sponse to chemotherapeutic agents may depend on the p53 path-
way. WSU-HN12 cells have p53 mutations resulting in loss of p53 
protein. This may explain why WSU-HN12 required higher IC50 
doses of entinostat compared with the WSU-HN6.
We also evaluated the effects of the entinostat on the cell cycle 
progression. We found that entinostat is effective in inducing cell 
cycle arrest in G0/G1 in all cell lines we have tested, including normal 
keratinocyte cell line. We have, however, observed that entinostat 
could selectively inhibit tumor cells entry on S phase when com-
pared to normal keratinocyte cells. Parallel to these observations, 
an increase in p21 tumor suppressor protein (Cdkn1a) levels was 
also observed in all cells independent from the p53 status. Aligned 
with our results, the knockdown of p53 in colon carcinoma cell lines 
interfered with cytotoxicity of the HDAC inhibitors, which also in-
duced the expression of Acetyl-H4 and p21.20,23 The process of 
the cell cycle is regulated by cyclin-dependent kinase (Cdk)-cyclin 
complexes in eukaryotic cells. During carcinogenesis, the cell cycle 
is frequently found deregulated, and Cdks are often involved in the 
maintenance of tumor proliferation. In cancer cells, p21 binds and 
inactivates cyclin/Cdk complexes resulting in G1 cell cycle arrest.24 
Here, we found that entinostat mediates the accumulation of p21 
followed by increased cell cycle arrest in G0/G1.
Histone modifications, including the deacetylation of histones 
H3 and H4, can be induced by HDACs. These modifications result 
in the decondensation of the chromatin and subsequent gene re-
pression.25 Thus, as an HDAC inhibitor, entinostat, is effective in en-
hancing histone acetylation in OSCC cells. In this study, we observed 
increased expression of acetylated histones H3 and H4 after treat-
ment with HDACi. Entinostat decreased the expression of the SIRT1, 
a nicotinamide adenine dinucleotide (NAD+)–dependent deacetyl-
ase that applies its biological action by deacetylating histones and 
non-histone protein. Interestingly, recent investigations showed that 
entinostat is a potent inhibitor of cellular NAD+, which in turn af-
fects SIRT1.26,27 Indeed, inhibition of NAD+ decreases sirtuins, such 
as SIRT1, SIRT3, and SIRT6.27 SIRT1 is upregulated in many cancers, 
including breast, ovarian, pancreatic, colorectal, prostate, gastric, 
and hepatocellular carcinoma. SIRT1 enhances cancer cell survival 
by improving resistance to apoptosis, inducing angiogenesis, and 
resistance to chemotherapy.28,29 These findings are related to unsat-
isfactory clinical outcomes in cancer patients, such as higher tumor 
stage, lymph node metastasis, chemoresistance, and elevated cell 
proliferation.29 Thus, SIRT1 has been an attractive target for cancer 
therapy.
Epigenetic modifications can affect HNSCC stem cells, which 
are an important factor for tumor development and progression.4,30 
CSCs also contribute to radio-chemotherapy resistance, which can 
result in tumor relapse. Thereby, targeting CSCs remains an attrac-
tive therapeutic strategy. Current methods used to recognize and 
isolate CSCs from the head and neck cancers involve the identifica-
tion of the membrane marker CD44 combined with high enzymatic 
activity of aldehyde dehydrogenase (ALDH). Here, we showed that 
CSCs are sensitive to entinostat. Also, the expression of BMI1, a pro-
tein related to CSC proliferation and growth, was decreased in the 
OSCC cells. These results indicate that chemical inhibition of HDAC 
reduces the number of CSCs.
Entinostat and other HDAC inhibitors are entering into clinical 
trials. A multicenter phase II study testing entinostat and 5-azac-
itidine (5-AZA) in women with advanced hormone-resistant or 
triple-negative breast cancer was initiated in 2017.7 Initially, re-
cruited patients underwent a regiment of 5-AZA and entinostat for 
28 days, and the epigenetic therapy was further prolongated with 
the addition of endocrine therapy. Results from the optional pro-
longed therapy suggested that some women benefit from epigen-
etic therapy, along with the reintroduction of endocrine therapy 
beyond progression. Overall, the combination therapy of 5-AZA 
and entinostat was well-tolerated by the patients. Additionally, 
the PEMDAC study was the first trial to assess the addition of the 
HDAC inhibitor entinostat in the management of melanoma of the 
eye treated with pembrolizumab, an anti-PD1 drug.8
All things considered, our findings demonstrated that patients 
with OSCC might benefit from therapies using HDAC inhibitors such 
as entinostat. Entinostat promoted a cytotoxic effect on OSCC as 
well as cell cycle disruption and increased production and accumu-
lation of intracellular levels of ROS. Combined, entinostat increased 
the number of tumor cells undergoing apoptosis and reduced the 
CSCs. These findings suggest that entinostat is a promising thera-
peutic agent in the management of oral cancer.
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